Mark Mapstone

picture of Mark  Mapstone

Professor of Clinical Neurology
School of Medicine

Chief, Neuropsychology Division
School of Medicine

Faculty, Institute for Memory Impairments and Neurological Disorders (UCI MIND)

Fellow, Center for the Neurobiology of Learning and Memory

Co-Director, Center for Aging Research in Down Syndrome
School of Medicine


Ph.D., Northwestern University, 2000, Clinical Psychology

ORCiD: 0000-0003-0280-8057

Phone: (949) 824-7184
Email: mark.mapstone@uci.edu

University of California, Irvine
318 Sprague Hall
839 Health Sciences Road
Mail Code: 3910
Irvine, CA 92697
Research Interests
Cognitive Phenotyping, Biomarkers of Neurological Disease, Cognitive Neuroscience
Academic Distinctions
1996, University Scholar, The Graduate School, Northwestern University
1998, Fellow, Buehler Center on Aging, Northwestern University Medical School
2000, George Yacorzinski Scholar, Northwestern University Medical School
2001, NIH Post-doctoral Fellowship, University of Rochester
2003, NIH Career Development Award (K23)
2004, John Henry Hobart Fellow in Ethics and Social Justice, Hobart College
Appointments
2000-2002, Post-doctoral Fellow, Clinical Neuropsychology, University of Rochester School of Medicine
2002-2008, Assistant Professor, Neurology, University of Rochester School of Medicine
2008-2015, Associate Professor, Neurology, University of Rochester School of Medicine
2015- present, Adjunct Professor, Neurology, University of Rochester School of Medicine
Research Abstract
I am a translational neuroscientist. My goal is to translate discoveries about the aging brain into practical and implementable approaches for successful cognitive aging at the individual level. My current work is focused on early detection of age-related neurological disease especially Alzheimer’s disease and Parkinson’s disease using careful cognitive phenotyping and biomarkers obtained from blood. We are using this information to develop screening tools that can be used to enrich clinical trials with appropriate subjects for disease modifying interventions. We hope to develop reliable biomarkers for clinical use.
Publications
Publications from the past 3 years (2018-2021)
1. Chapman BP, Benedict RHB, Lin F, Roy S, Porteinsson A, Szigeti K, Federoff H, Mapstone M. Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype. International journal of geriatric psychiatry. 2018;33(2):332-9. Epub 2017/06/15. doi: 10.1002/gps.4748. PubMed PMID: 28612377.
2. Chapman RM, Gardner MN, Klorman R, Mapstone M, Porsteinsson AP, Antonsdottir IM, Kamalyan L. Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease. Alzheimers Dement (Amst). 2018;10:604-14. Epub 2018/11/13. doi: 10.1016/j.dadm.2018.08.002. PubMed PMID: 30417070; PMCID: PMC6215980.
3. Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, Federoff HJ. Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. Metabolites. 2018;8(3). Epub 2018/09/13. doi: 10.3390/metabo8030050. PubMed PMID: 30205491; PMCID: PMC6161135.
4. Fiandaca MS, Mapstone M, Mahmoodi A, Gross T, Macciardi F, Cheema AK, Merchant-Borna K, Bazarian J, Federoff HJ. Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PloS one. 2018;13(4):e0195318. Epub 2018/04/21. doi: 10.1371/journal.pone.0195318. PubMed PMID: 29677216; PMCID: PMC5909890.
5. Gross T, Mapstone M, Miramontes R, Padilla R, Cheema AK, Macciardi F, Federoff HJ, Fiandaca MS. Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development. Curr Top Med Chem. 2018;18(11):883-95. Epub 2018/07/12. doi: 10.2174/1568026618666180711144323. PubMed PMID: 29992885.
6. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018;130:331-65. Epub 2018/02/20. doi: 10.1016/j.phrs.2018.02.014. PubMed PMID: 29458203.
7. Zimmermann J, Perry A, Breakspear M, Schirner M, Sachdev P, Wen W, Kochan NA, Mapstone M, Ritter P, McIntosh AR, Solodkin A. Differentiation of Alzheimer's disease based on local and global parameters in personalized Virtual Brain models. Neuroimage Clin. 2018;19:240-51. Epub 2018/07/24. doi: 10.1016/j.nicl.2018.04.017. PubMed PMID: 30035018; PMCID: PMC6051478.
8. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S, Alzheimer Precision Medicine I. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018;130:331-65. Epub 2018/02/20. doi: 10.1016/j.phrs.2018.02.014. PubMed PMID: 29458203.
9. Wang X, Ren P, Baran TM, Raizada RDS, Mapstone M, Lin F. Longitudinal Functional Brain Mapping in Supernormals. Cerebral cortex. 2019;29(1):242-52. Epub 2017/12/01. doi: 10.1093/cercor/bhx322. PubMed PMID: 29186360; PMCID: PMC6294410.
10. Gross TJ, Doran E, Cheema AK, Head E, Lott IT, Mapstone M. Plasma Metabolites Related to Cellular Energy Metabolism Are Altered in Adults with Down Syndrome and Alzheimer's Disease. Developmental neurobiology. 2019. Epub 2019/08/17. doi: 10.1002/dneu.22716. PubMed PMID: 31419370.
11. Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Lucia A, Mapstone M, Verdooner SR, Woodcock J, Lista S. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues Clin Neurosci. 2019;21(2):177-91. Epub 2019/10/23. PubMed PMID: 31636492; PMCID: PMC6787542.
12. Wang X, Ren P, Baran TM, Raizada RDS, Mapstone M, Lin F, Alzheimer's Disease Neuroimaging I. Longitudinal Functional Brain Mapping in Supernormals. Cerebral cortex. 2019;29(1):242-52. Epub 2017/12/01. doi: 10.1093/cercor/bhx322. PubMed PMID: 29186360; PMCID: PMC6294410.
13. Wang X, Ren P, Mapstone M, Conwell Y, Porsteinsson AP, Foxe JJ, Raizada RDS, Lin F, and the Alzheimer's Disease Neuroimaging I. Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer's pathology. Brain Imaging Behav. 2019;13(1):53-64. Epub 2017/09/16. doi: 10.1007/s11682-017-9767-y. PubMed PMID: 28913718; PMCID: PMC5854501.
14. Toschi N, Lista S, Baldacci F, Cavedo E, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, dos Santos AM, Epelbaum S, Lamari F, Genthon R, Habert MO, Dubois B, Floris R, Garaci F, Vergallo A, Hampel H, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Babiloni C, Baldacci F, Batrla R, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Emanuele E, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Goetzl EJ, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Kapogiannis D, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lemercier P, Lista S, Lorenceau J, Lucia A, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Palermo G, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E, grp IPS, APMI. Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of aging. 2019;83:42-53. doi: 10.1016/j.neurobiolaging.2019.08.032. PubMed PMID: WOS:000499079800005.
15. Gross TJ, Doran E, Cheema AK, Head E, Lott IT, Mapstone M. Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease. Developmental neurobiology. 2019;79(7):622-38. doi: 10.1002/dneu.22716. PubMed PMID: WOS:000483618400001.
16. Chiesa PA, Cavedo E, Vergallo A, Lista S, Potier MC, Habert MO, Dubois B, de Schotten MT, Hampel H, Bakardjian H, Benali H, Bertin H, Bonheur J, Boukadida L, Boukerrou N, Chiesa P, Colliot O, Dubois M, Epelbaum S, Gagliardi G, Genthon R, Houot M, Kas A, Lamari F, Levy M, Metzinger C, Mochel F, Nyasse F, Poisson C, Revillon M, Santos A, Andrade KS, Sole M, Surtee M, de Schotten MT, Younsi N, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Avila J, Babiloni C, Baldacci F, Batrla R, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Castrillo J, Ceravolo R, Corvol JC, Cuello AC, Cummings JL, Depypere H, Duggento A, Emanuele E, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Goetzl EJ, Graziani M, Haberkamp M, Herholz K, Hernandez F, Kapogiannis D, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lucia A, Lorenceau J, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Palermo G, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Villain N, Welikovitch LA, Woodcock J, Younesi E, Grp I-pS, Initiative APM. Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimers & Dementia. 2019;15(7):940-50. doi: 10.1016/j.jalz.2019.03.006. PubMed PMID: WOS:000475846300009.
17. Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Lucia A, Mapstone M, Verdooner SR, Woodcock J, Lista S, Apmi. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues Clin Neuro. 2019;21(2):177-91. doi: 10.31887/DCNS.2019.21.2/hhampel. PubMed PMID: WOS:000478803900008.
18. Vergallo A, Megret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H, Dubois B, Hampel H, Bakardjian H, Benali H, Colliot O, Marie-O H, Lamari F, Mochel F, Potier MC, de Schotten MT, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Avila J, Babiloni C, Baldacci F, Batrla R, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Emanuele E, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Goetzl EJ, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Hernandez F, Kapogiannis D, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lucia A, Lista S, Lorenceau J, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Palmero G, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E, Grp I-PS, APMI. Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimers & Dementia. 2019;15(6):764-75. doi: 10.1016/j.jalz.2019.03.009. PubMed PMID: WOS:000470084500004.
19. Hampel H, Goetzl EJ, Kapogiannis D, Lista S, Vergallo A, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Babiloni C, Baldacci F, Batrla R, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Emanuele E, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Graziani M, Haberkamp M, Habert MO, Herholz K, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lucia A, Lorenceau J, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Palermo G, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Villain N, Welikovitch LA, Woodcock J, Younesi E, Initiative APM. Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. Frontiers in Pharmacology. 2019;10. doi: ARTN 310 10.3389/fphar.2019.00310. PubMed PMID: WOS:000462769400002.
20. Wang XX, Ren P, Mapstone M, Conwell Y, Porsteinsson AP, Foxe JJ, Raizada RDS, Lin F, In AsDN. Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer's pathology. Brain Imaging and Behavior. 2019;13(1):53-64. doi: 10.1007/s11682-017-9767-y. PubMed PMID: WOS:000460795600005.
21. Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H, Bakardjian H, Benali H, Bertin H, Bonheur J, Boukadida L, Boukerrou N, Cavedo E, Chiesa P, Colliot O, Dubois B, Dubois M, Epelbaum S, Gagliardi G, Genthon R, Habert MO, Hampel H, Houot M, Kas A, Lamari F, Levy M, Lista S, Metzinger C, Mochel F, Nyasse F, Poisson C, Potier MC, Revillon M, Santos A, Andrade KS, Sole M, Surtee M, de Schotten MT, Vergallo A, Younsi N, Dubois B, Hampel H, Bakardjian H, Benali H, Colliot O, Marie-O H, Lamari F, Mochel F, Potier MC, Thiebaut DM, Aguilar LF, Babiloni C, Baldacci F, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Bun RS, Cacciola F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Colliot O, Coman CM, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Durrleman S, Escott-Price V, Feder-Off H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Genthon R, George N, Giorgi FS, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Karran E, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehericy S, Lista S, Lorenceau J, Mapstone M, Neri C, Nistico R, Nyasse-Messene F, O'Bryant SE, Perry G, Ritchie C, Rojkova K, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E, Grp IPS, APMI. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Research & Therapy. 2019;11. doi: ARTN 15
10.1186/s13195-019-0466-3. PubMed PMID: WOS:000457434600003.
22. Hampel H, Lista S, Mango D, Nistico R, Perry G, Avila J, Hernandez F, Geerts H, Vergallo A, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Babiloni C, Baldacci F, Batrla R, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Cas-Trillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Emanuele E, Escott-Price V, Emerge H, Ferretti MT, Fian-Daca M, Frank RA, Garaci F, Giorgi FS, Goetzl EJ, Graziani M, Haberkamp M, Habert M, Hampel, Herholz K, Kapogiannis D, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lucia A, Lorenceau J, Mapstone M, Neri C, O'bryant SE, Palermo G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo, Villain N, Welikovitch LA, Woodcock J, Younesi E, Initiative APM. Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. Journal of Alzheimers Disease. 2019;69(3):615-29. doi: 10.3233/Jad-190197. PubMed PMID: WOS:000471781600002.
23. Hampel H, Lista S, Vergallo A, Afshar M, Aguilar LF, Akman-Anderson L, Arenas J, Batrla R, Babiloni C, Baldacci F, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Caraci F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Emanuele E, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Goetzl EJ, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Kapogiannis D, Karran E, Kiddle SJ, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lucia A, Lista S, Lorenceau J, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Palermo G, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E, Apmi. Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. Jpad-J Prev Alzheim. 2019;6(3):182-4. doi: 10.14283/jpad.2019.22. PubMed PMID: WOS:000468000700012.
24. Hampel H, Vergallo A, Perry G, Lista S, Aguilar LF, Babiloni C, Baldacci F, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Cacciola F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Geerts H, Giorgi FS, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Karran E, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Langevin T, Lehericy S, Lista S, Lorenceau J, Mango D, Mapstone M, Neri C, Nistico R, O'Bryant SE, Perry G, Ritchie C, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E, Apmi. The Alzheimer Precision Medicine Initiative. Journal of Alzheimers Disease. 2019;68(1):1-24. doi: 10.3233/Jad-181121. PubMed PMID: WOS:000461051200001.
25. Chen Q, Baran TM, Rooks B, O'Banion MK, Mapstone M, Zhang Z, Lin F, Alzheimer's Disease Neuroimaging I. Cognitively supernormal older adults maintain a unique structural connectome that is resistant to Alzheimer's pathology. Neuroimage Clin. 2020;28:102413. Epub 2020/09/25. doi: 10.1016/j.nicl.2020.102413. PubMed PMID: 32971466; PMCID: PMC7511768.
26. Handen BL, Lott IT, Christian BT, Schupf N, S OB, Mapstone M, Fagan AM, Lee JH, Tudorascu D, Wang MC, Head E, Klunk W, Ances B, Lai F, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Andrews H, Hartley S, Silverman W, Alzheimer's Biomarker Consortium-Down S. The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimers Dement (Amst). 2020;12(1):e12065. Epub 2020/08/11. doi: 10.1002/dad2.12065. PubMed PMID: 32775597; PMCID: PMC7396809.
27. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Ances BM, Wang MC, Tycko B, Lee JH, O'Bryant S, Alzheimer's Biomarker Consortium - Down S. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. Alzheimers Dement (Amst). 2020;12(1):e12039. Epub 2020/07/07. doi: 10.1002/dad2.12039. PubMed PMID: 32626817; PMCID: PMC7327223 medicine in neurodegenerative diseases and served on an Advisory Board to Roche Diagnostics. No other authors have conflicts of interest to disclose.
28. Mapstone M, Gross TJ, Macciardi F, Cheema AK, Petersen M, Head E, Handen BL, Klunk WE, Christian BT, Silverman W, Lott IT, Schupf N, Alzheimer's Biomarkers Consortium-Down Syndrome I. Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020;12(1):e12028. Epub 2020/04/08. doi: 10.1002/dad2.12028. PubMed PMID: 32258359; PMCID: PMC7131985.
29. Gross TJ, Cheema AK, Espeland MA, O'Bryant S, Cotman CW, Baker LD, Mapstone M. Aerobic exercise effects on the peripheral plasma lipidome in mild cognitive impairment: The influence of prediabetes: Biomarkers (non-neuroimaging)/plasma/serum/urine biomarkers. Alzheimer's & Dementia. 2020;16:e046595.
30. Lao PJ, Luo L, Igwe KC, Rizvi B, Sathishkumar M, Rosas HD, Lai F, Mapstone M, Head E, Silverman W. Cross-sectional and longitudinal associations of white matter hyperintensities and cortical thickness in the biomarkers of Alzheimer’s Disease in Down Syndrome (ADDS) study: Neuroimaging/imaging and genetics. Alzheimer's & Dementia. 2020;16:e045344.
31. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease. 2020(Preprint):1-11.
32. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12039.
33. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B. The AT (N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12062.
34. Yilmaz A, Ustun I, Ugur Z, Akyol S, Hu WT, Fiandaca MS, Mapstone M, Federoff H, Maddens M, Graham SF. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease. 2020(Preprint):1-12.
Grants
R01 AG058644 (Mapstone, PI) Multi-omic Investigation of Exercise Effects in MCI
U19 AG068054 (Handen, Christian, Head, Mapstone) The Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS)
U54 AG05439 supplement (LaFerla) Lipid and Energy Metabolism in MODEL-AD Mice
U01 AG051412 supplement (Schupf) Expanded metabolomic analysis of Mild Cognitive Impairment and Dementia in Adults with Down Syndrome
U01 AG051406 supplement (Handen) Metabolomics for Down Syndrome Phenoconversion to Dementia
R01 AG056726 (Pausova) Visceral fat, neuroinflammation and brain health: Towards early detection and prevention of preclinical dementia
R01 AG065314 (Chapman) Brain ERPs to assess emotional function in normal aging and MCI/AD
Professional Societies
Society for Neuroscience
International Neuropsychology Society
International Society for Behavioral Neuroscience
American Academy of Neurology
Graduate Programs
Interdepartmental Neuroscience Program

Neurology

Research Center
Center for Aging Research in Down Syndrome
Last updated
03/08/2021